SCYNEXIS Ibrexafungerp: Positive Activity in Infections Including Candida

Six presentations will provide additional evidence of the potent and broad antifungal activity of oral ibrexafungerp, including new clinical case studies from the CARES and FURI trials as well as promising preclinical data

Case studies from the CARES trial, the first study of an investigational agent to treat patients with Candida auris infections, show favorable outcomes following treatment with oral ibrexafungerp

Ibrexafungerp shows strong clinical activity in difficult-to-treat patients with resistant Candida pathogens in a variety of infections, including esophageal candidiasis and spondylodiscitis (FURI study)

SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced data demonstrating the potential use of ibrexafungerp as an agent to address multiple serious fungal infections, including many that have shown resistance to existing therapies. The collection of data will be presented in one oral and five poster presentations at the 29^th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 13-16, 2019, in Amsterdam, Netherlands.

https://www.prnewswire.com/news-releases/scynexiss-ibrexafungerp-shows-favorable-clinical-activity-in-resistant-fungal-infections-including-candida-auris-cases-from-the-cares-study-in-data-to-be-presented-at-the-29th-eccmid-300823802.html